Vazyme(SH:688105) Zheng Quan Zhi Xing·2025-06-19 10:42Core Viewpoint - Nanjing Novogene Bioinformatics Technology Co., Ltd. plans to repurchase its shares through centralized bidding, with a total repurchase amount ranging from RMB 5 million to RMB 10 million, aimed at implementing equity incentives or employee stock ownership plans [1][4][6]. Summary by Relevant Sections Repurchase Plan Details - The repurchase amount is set between RMB 5 million and RMB 10 million [1][4]. - The funding source for the repurchase will be the company's own funds [1][4]. - The maximum repurchase price is capped at RMB 30 per share, which does not exceed 150% of the average trading price over the last 30 trading days prior to the board's decision [1][4][6]. - The repurchase will be conducted through the Shanghai Stock Exchange's trading system [1][5]. - The duration for the repurchase is within 12 months from the board's approval date [1][4]. Purpose and Use of Repurchased Shares - The repurchased shares will be used for implementing equity incentives or employee stock ownership plans [1][4][8]. - If the company fails to implement these plans within three years after the repurchase, the unutilized shares will be canceled [1][4][12]. Shareholder and Management Plans - Major shareholders, including the actual controller and board members, have no plans to reduce their holdings in the next three to six months [2][10][11]. - The proposal for the repurchase was initiated by the actual controller and chairman, Mr. Cao Lin, based on confidence in the company's future development [12][13]. Financial Impact and Structure Changes - As of March 31, 2025, the company's total assets were RMB 5.266 billion, with net assets attributable to shareholders at RMB 3.901 billion [8]. - The repurchase amount, if at the upper limit of RMB 10 million, would represent approximately 0.02% of total assets and 0.26% of net assets [8]. - The repurchase is expected to have no significant impact on the company's operations, financial status, or future development [8]. Compliance and Authorization - The repurchase plan has been approved by more than two-thirds of the board members and does not require shareholder meeting approval [3][4]. - The management is authorized to handle all matters related to the repurchase, including adjustments to the plan as necessary [13][14].